Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Investing.com - Bernstein SocGen Group has reiterated an Outperform rating on Regeneron Pharmaceuticals (NASDAQ: REGN) with a price target of $750.00.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company ...

Investing.com - JPMorgan has maintained its Overweight rating and $800.00 price target on Regeneron Pharmaceuticals (NASDAQ:REGN) ahead of the company’s second-quarter earnings report. The ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Morgan Stanley slightly lowered its price target for Regeneron Pharmaceuticals while maintaining an overweight rating, ...

Regeneron Pharmaceuticals, Inc. (REGN) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings.

Several companies on Wall Street have seen recent Seeking Alpha analyst activity, including both upgrades and downgrades.

DekaBank Deutsche Girozentrale increased its stake in Regeneron Pharmaceuticals by 4.7% this quarter, now holding 221,176 ...

Regeneron Pharmaceuticals Inc. research and ratings by Barron's. View RGO revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.